Companies Dominating the Expanded Hemodialysis Therapy Landscape
- B. Braun Melsungen AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Asahi Kasei Corporation
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Nikkiso Co., Ltd.
- Nipro Corporation
- NxStage Medical, Inc.
- Cantel Medical Corp.
- Satellite Healthcare, Inc.
- MEDIVATORS, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of expanded hemodialysis therapy is evaluated at USD 95.07 billion.
The expanded hemodialysis therapy market size was over USD 88.03 billion in 2024 and is poised to exceed USD 163.95 billion by 2037, growing at over 4.9% CAGR during the forecast period i.e., between 2025-2037. The market growth is propelled by growing prevalence of diabetes and hypertension and increasing technological advancements to develop innovative therapies.
North America industry is expected to hold largest revenue share of 35% by 2037, propelled by rising healthcare expenditure, growing disposable income, and rising demand for the development of new products.
The major players in the market are B. Braun Melsungen AG, Asahi Kasei Corporation, Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., Nipro Corporation, NxStage Medical, Inc., Cantel Medical Corp., Satellite Healthcare, Inc., MEDIVATORS, Inc.
